Hyderabad-based Bharat Biotech is likely to get approval from the World Health Organization in two weeks for the emergency use listing (EUL) of its Covaxin vaccine, according to NK Arora, who is heading the National Technical Advisory Group on Immunisation (NTAGI.
EUL is a WHO procedure through which it assesses the medicines, vaccines and devices used to address an outbreak classified as a ‘public health emergency of international concern’. With the approval for EUL, Bharat Biotech will be able to supply its vaccine to other countries. The Hyderabad-based company had applied to WHO for EUL in the second week of July.
Covaxin, the company’s home-grown Covid-19 vaccine approved for emergency use in India, is one of two shots driving the country’s massive vaccination programme launched on January 16.
On Sunday, the company rolled out the first batch of Covaxin shots from a facility in Ankleshwar in western India that has the capacity to produce more than 1 crore doses per month.
